New Delhi [India], August 5 (ANI): The Central Board for Indirect Taxes and Customs (CBIC) on Wednesday launched the Indian Customs Compliance Information Portal (CIP) for providing free access to information on all customs procedures and regulatory compliance for nearly 12,000 customs tarif
New Delhi [India], August 3 (ANI): Nearly 2.01 crore beneficiaries are covered under National Food Security Act (NFSA) in Chhattisgarh, the Central government informed in the Lok Sabha on Tuesday.
Mumbai (Maharashtra) [India], July 28 (ANI): Equity frontline indices suffered losses amid weak global trends on Wednesday with auto and banking stocks bearing the brunt of a huge selloff.
Mumbai (Maharashtra) [India], July 28 (ANI): Equity indices suffered losses during early hours on Wednesday with all sectoral benchmarks in the negative zone.
Mumbai (Maharashtra) [India], July 27 (ANI): Equity benchmark indices shaved early gains and closed half a per cent lower on Tuesday with pharma stocks being the worst sufferers.
New Delhi [India], July 3 (ANI/PNN): With the world being revolutionised by the emergence of internet evolution, every human on the planet relies on digital mediums to find a solution to almost all of their problems.
New Delhi [India], June 29 (ANI): The Mumbai-based pharmaceutical multinational Cipla, on behalf of the US pharma major Moderna, has requested for import and marketing authorisation of its COVID-19 vaccines.
Mumbai (Maharashtra) [India], June 22 (ANI): Equity benchmark indices extended recovery during early hours on Tuesday as investors focussed on economic growth amid favourable cues from their global peers.
Mumbai (Maharashtra) [India], June 10 (ANI): Key equity parameters traded gap up during early hours on Thursday with metal, realty and pharma stocks showing marginal gains.
Mumbai (Maharashtra) [India], June 7 (ANI): Equity benchmark indices traded flat during early hours on Monday amid lack of any major domestic trigger and subdued Asian markets.
New Delhi [India], May 24 (ANI): Drug major Roche India on Monday announced the launch of its first batch of antibody cocktail against COVID-19 in India. The antibody cocktail -- Casirivimab and Imdevimab -- is priced at Rs 59,750 per dose.